RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Zhejiang Hisun Pharma reported that favilavir, a generic anti-viral, has been approved by China’s NMPA to treat COVID-19, the first approved treatment for the viral outbreak. According to unofficial reports, fapilavir showed efficacy with only minor side effects in an ongoing 70-patient clinical trial in Shenzhen, Guangdong province. The size of the trial and its “ongoing” nature imply that the approval will require further proof before it becomes permanent. Favilavir is a generic version of Fapilavir, an anti-catarrhal drug that clears mucous from the mucous membranes of the airway.
Source: China Biotoday